First in human randomized, double-blind, placebo controlled single ascending dose (SAD) phase I study
Ended Awarded Last action
- Contract number
- 75N95024F00001
- Awardee
-
PPD Development LP UEI ZANENSW6C665
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,773,098
Award facts
- Contract value 85% obligated
-
- $2,773,098.00 Current, with exercised options
- $3,265,588.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Cape Fear, NC 28401, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $2,345,049 | |
| Original award | $428,049 |
About this award
This is a $3,265,588.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute on Drug Abuse (NIDA), a part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS), to PPD Development LP, a global contract research organization. The contract is for a first-in-human randomized, double-blind, placebo-controlled single ascending dose (SAD) Phase I study on the development of neurotherapeutics. The contract is not set aside and is part of a larger Phase I Clinical Trials for Development of Neurotherapeutics Indefinite Delivery Vehicle (IDV) contract. PPD Development LP has significant experience supporting various federal medical research initiatives, including past contracts and grants from NIH, Department of Defense, and HHS.
Quick answers
Who was awarded contract 75N95024F00001?
75N95024F00001 was awarded to PPD Development LP by National Institute on Drug Abuse (National Institutes of Health) on July 8, 2016.
How much is contract 75N95024F00001 worth?
The government has obligated $2,773,098 on 75N95024F00001. Its potential value, with all options, is $3,265,588.
Is contract 75N95024F00001 an order under another contract?
Yes. 75N95024F00001 is a delivery order under HHSN271201600005I, an indefinite delivery contract, on Phase I Clinical Trials for Development of Neurotherapeutics.
Was contract 75N95024F00001 competed?
The extent of competition for 75N95024F00001 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award